Technology CEO selected to lead Praemium

appointments chief executive australian securities exchange

6 September 2011
| By Chris Kennedy |

Praemium has selected the former chief executive of Vision BioSystems and Genetic Technologies, Michael Ohanessian, as its new group chief executive.

Ohanessian's terms of appointment include a $400,000 per annum base salary plus superannuation, with a notice period of nine months, according to a statement on the Australian Securities Exchange.

Short-term incentives include a bonus of 30 per cent of base salary on achievement of budget EBIT (earnings before interest and tax) and up to a maximum of 50 per cent based on outperformance, the statement read.

For long-term incentives, Ohanessian will be granted one million options having a five year term which will be exercisable from 10 August 2013 to 9 August 2016; the exercise price will be 15 cents in the first year, 25 cents in the second, and 35 cents in the third year of that period.

Ohanessian will also be entitled to participate in the Praemium directors and employees benefits plan and will be issued with five million performance rights which will be vested on achievement of key performance indicators.

Ohanessian previously had a 10-year career at Mobil Oil, and worked at Boston Consulting Group before his roles at Vision BioSystems and Genetic Technologies. More recently, he has been involved in investment management and corporate advice with Lion Capital.

He will work particularly closely with Praemium's UK team to expand its presence in the UK financial services market, Praemium stated.

Homepage

Read more about:

AUTHOR

Recommended for you

sub-bgsidebar subscription

Never miss the latest news and developments in wealth management industry

MARKET INSIGHTS

Completely agree Peter. The definition of 'significant change is circumstances relevant to the scope of the advice' is s...

1 month 2 weeks ago

This verdict highlights something deeply wrong and rotten at the heart of the FSCP. We are witnessing a heavy-handed, op...

1 month 2 weeks ago

Interesting. Would be good to know the details of the StrategyOne deal....

1 month 3 weeks ago

SuperRatings has shared the median estimated return for balanced superannuation funds for the calendar year 2024, finding the year achieved “strong and consistent positiv...

6 days ago

Insignia Financial has confirmed it is considering a preliminary non-binding proposal received from a US private equity giant to acquire the firm. ...

4 weeks 1 day ago

Six of the seven listed financial advice licensees have reported positive share price growth in 2024, with AMP and Insignia successfully reversing earlier losses. ...

3 weeks 4 days ago

TOP PERFORMING FUNDS